article · Endocrine Metabolic & Immune Disorders - Drug Targets
A part of our concern about fatty liver disease awareness without trivialization. The use of the word "fat" in the nomenclature of fatty liver disease linked with metabolic dysfunction is not perceived to be stigmatizing. The suggested change to MASLD does not seem warranted, at least if the stigma is the main concern.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2174/0118715303359141250420070406
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
